NEUE · As filed with the SEC
NeueHealth income statement, by fiscal year
The statement as NeueHealth presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF INCOME (LOSS) · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|
| Revenue: | |||
| Capitated revenue | 259,881 | 219,774 | 112,904 |
| Service revenue | 50,393 | 44,438 | 39,601 |
| ACO REACH revenue | 625,339 | 896,504 | 654,087 |
| Investment income | 1,044 | 86 | (55,429) |
| Total revenue | 936,657 | 1,160,802 | 751,163 |
| Operating expenses: | |||
| Medical costs | 742,140 | 996,582 | 662,972 |
| Operating costs (including gain on disposal of $1,185 and $0, respectively) | 273,900 | 287,138 | 354,436 |
| Bad debt expense | 14 | 27,407 | 12 |
| Restructuring charges | 956 | 6,990 | 29,178 |
| Goodwill impairment | 0 | 401,385 | 0 |
| Intangible assets impairment | 11,411 | 0 | 42,611 |
| Depreciation and amortization | 15,646 | 18,296 | 30,710 |
| Total operating expenses | 1,044,067 | 1,737,798 | 1,119,919 |
| Operating loss | (107,410) | (576,996) | (368,756) |
| Interest expense | — | 38,203 | 12,822 |
| Interest expense | 18,701 | — | — |
| Warrant expense | 3,661 | 13,971 | 0 |
| Gain on troubled debt restructuring | (30,311) | — | — |
| Loss from continuing operations before income taxes | (99,461) | (629,170) | (381,578) |
| Income tax expense (benefit) | 2,597 | (1,428) | 3,664 |
| Net loss from continuing operations | (102,058) | (627,742) | (385,242) |
| Gain (Loss) from discontinued operations, net of tax (including gain on disposal of $66,201 and $0, respectively) (Note 19) | 2,341 | (638,066) | (974,638) |
| Net loss | (99,717) | (1,265,808) | (1,359,880) |
| Net (income) loss from continuing operations attributable to noncontrolling interests | (34,963) | 114,354 | (95,664) |
| Redeemable Series A preferred stock | (42,184) | (40,139) | (37,889) |
| Redeemable Series B preferred stock | (9,466) | (9,006) | (1,798) |
| Net loss attributable to NeueHealth, Inc. common shareholders | (186,330) | (1,200,599) | (1,495,231) |
| Basic and diluted (loss) income per share attributable to NeueHealth, Inc. common shareholders | |||
| Continuing operations, basic (in dollars per share) | (22.93) | (70.72) | (66.17) |
| Continuing operations, diluted (in dollars per share) | (22.93) | (70.72) | (66.17) |
| Discontinued operations, basic (in dollars per share) | 0.28 | (80.22) | (123.87) |
| Discontinued operations, diluted (in dollars per share) | 0.28 | (80.22) | (123.87) |
| Basic loss per share (in dollars per share) | (22.65) | (150.94) | (190.04) |
| Diluted loss per share (in dollars per share) | (22.65) | (150.94) | (190.04) |
| Basic weighted-average common shares outstanding (in shares) | 8,226 | 7,954 | 7,868 |
| Diluted weighted-average common shares outstanding (in shares) | 8,226 | 7,954 | 7,868 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.